Most bothersome symptom in women with genitourinary syndrome of menopause as a moderator of treatment effects

被引:3
作者
Pinkerton, JoAnn V. [1 ]
Bushmakin, Andrew G. [2 ]
Abraham, Lucy [3 ]
Cappelleri, Joseph C. [2 ]
Komm, Barry S. [4 ]
机构
[1] Univ Virginia Hlth Syst, Charlottesville, VA USA
[2] Pfizer Inc, Groton, CT 06340 USA
[3] Pfizer Ltd, Tadworth, Surrey, England
[4] Pfizer Inc, Collegeville, PA USA
来源
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY | 2016年 / 23卷 / 10期
关键词
Bazedoxifene; Conjugated estrogens; Genitourinary syndrome of menopause; Menopause; Quality of life; Vagina; Vulvar-vaginal atrophy; QUALITY-OF-LIFE; VULVO-VAGINAL ATROPHY; BAZEDOXIFENE/CONJUGATED ESTROGENS; POSTMENOPAUSAL WOMEN; SEXUAL HEALTH; QUESTIONNAIRE; VIEWS; PAIN;
D O I
10.1097/GME.0000000000000679
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective:Conjugated estrogens/bazedoxifene (CE/BZA) is indicated to treat moderate/severe menopausal vasomotor symptoms and prevent postmenopausal osteoporosis. This analysis examines the impact of the most bothersome vaginal symptom at baseline on effects of CE/BZA.Methods:This post hoc analysis used data from a 12-week clinical trial of nonhysterectomized postmenopausal women (n=664) randomly assigned to double-blind treatment with CE/BZA (0.45/20mg and 0.625/20mg), BZA 20mg, or placebo. At baseline, women indicated which moderate/severe vaginal symptom (dryness, itching/irritation, or pain with intercourse) bothered them most. Repeated measures models were used to explore treatment effects in relationship to the most bothersome symptom. We calculated effect sizes for treatment differences versus placebo (effect sizes: trivial, 0.1; small, 0.2; medium, 0.5; large, 0.8).Results:At baseline, 52% of women selected pain with intercourse, 35% selected vaginal dryness, and 13% selected vaginal itching/irritation as most bothersome. For these three symptom groups respectively, CE/BZA was associated with statistically significant improvements in Menopause-Specific Quality of Life sexual functioning (effect size: 0.45/20mg, -0.36, -0.30, -0.67; 0.625/20mg, -0.37, -0.40, -0.26) and/or overall score (effect size: 0.45/20mg, -0.29, -0.41, -0.78; 0.625/20mg, -0.41, -0.48, -0.68). Both those doses significantly improved the ease of lubrication item on the Arizona Sexual Experiences Scale in those with pain with intercourse (effect size: 0.45/20mg, -0.43; 0.625/20mg, -0.50) and produced some statistically significant improvements in vaginal cell counts in women with dryness or pain with intercourse as the most bothersome symptom. The higher dose was associated with greater treatment satisfaction on the Menopause Symptoms Treatment Satisfaction Questionnaire versus placebo in women who selected pain with intercourse (effect size: 0.40) or dryness (effect size: 0.43) as most bothersome.Conclusions:The approved dose of CE/BZA had clear benefits, particularly in women with pain with intercourse (the most common bothersome symptom), in whom it improved lubrication, superficial cell counts, and sexual functioning.
引用
收藏
页码:1092 / 1101
页数:10
相关论文
共 27 条
  • [1] [Anonymous], 2015, DUAV PACK INS
  • [2] Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy
    Bachmann, G.
    Bobula, J.
    Mirkin, S.
    [J]. CLIMACTERIC, 2010, 13 (02) : 132 - 140
  • [3] Examination of the Significant Placebo Effect in the Treatment of Interstitial Cystitis/Bladder Pain Syndrome
    Bosch, Philip C.
    [J]. UROLOGY, 2014, 84 (02) : 321 - 326
  • [4] Cappelleri JC, 2014, CH CRC BIOSTAT SER, P1
  • [5] Cohen J, 2013, Statistical power analysis for the behavioral sciences, DOI [10.4324/9780203771587, DOI 10.4324/9780203771587]
  • [6] Measuring symptom relief in studies of vaginal and vulvar atrophy: the most bothersome symptom approach
    Ettinger, Bruce
    Hait, Howard
    Reape, Kathleen Z.
    Shu, Haibin
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2008, 15 (05): : 885 - 889
  • [7] DYNAMICS AND SIGNIFICANCE OF PLACEBO-RESPONSE IN PRIMARY DYSMENORRHEA
    FEDELE, L
    MARCHINI, M
    ACAIA, B
    GARAGIOLA, U
    TIENGO, M
    [J]. PAIN, 1989, 36 (01) : 43 - 47
  • [8] Freedman MA, 2014, WOMENS HEALTH, V10, P445, DOI [10.2217/WHE.14.29, 10.2217/whe.14.29]
  • [9] A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17 beta combined with an oral progestin on quality of life in postmenopausal women
    Hilditch, JR
    Lewis, J
    Ross, AH
    Peter, A
    vanMaris, B
    Franssen, E
    Charles, J
    Norton, P
    Dunn, EV
    [J]. MATURITAS, 1996, 24 (03) : 177 - 184
  • [10] Development and preliminary validation of the Menopause Symptoms Treatment Satisfaction Questionnaire (MS-TSQ)
    Hill, Cheryl D.
    Fehnel, Sheri E.
    Bobula, Joel D.
    Yu, Holly
    McLeod, Lori D.
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2007, 14 (06): : 1047 - 1055